$18,271.51 research Payment -- Gilead Sciences to Dr. Matthew Walker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $18.3K research payment to Matthew Walker, a HIV Medicine specialist in City, VA. The payment was associated with Ozempic. Gilead Sciences made a research payment of $18,271.51 to Dr. Matthew Walker. The payment was related to research involving Ozempic. Dr. Walker specializes in HIV Medicine and is located in Virginia.

Patient Guidance: What This Payment Means for You

This payment was for research purposes and may contribute to the development of new treatments. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Research payments in HIV Medicine can vary widely depending on the scope and phase of the study.

Regulatory Context: Sunshine Act Requirements

Payments made by pharmaceutical companies to physicians for research activities are subject to disclosure under the Sunshine Act.

Related Topics

This payment is related to the following healthcare transparency topics:

• gilead-sciences
• matthew-walker
• hiv-medicine
• ozempic
• research-payment
• cms-open-payments

Understanding research Payments

Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.

Frequently Asked Questions About This Payment

What was this $18.3K payment for?

This was a research payment of $18.3K from Gilead Sciences to Matthew Walker, categorized as "Research". It was associated with Ozempic. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Matthew Walker accept pharmaceutical money?

Yes, Matthew Walker received this $18.3K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Matthew Walker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this research payment?

A research payment of $18.3K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in HIV Medicine?

To compare this payment against HIV Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. HIV Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Matthew Walker's relationship with Gilead Sciences?

The payment is categorized as 'research' under the 'Research' nature. This $18.3K research payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for HIV Medicine?

The specific drug associated with this research payment is Ozempic.

What should patients do after learning about this payment?

This payment was for research purposes and may contribute to the development of new treatments.

What else should I know about this research payment?

Dr. Walker's specialty is HIV Medicine, indicating a focus on infectious diseases.

Related Reports

• View Dr. Matthew Walker's full payment report
• Gilead Sciences full spending report
• Browse all HIV Medicine payments
• Browse all payments in Virginia
• Search for other payments